Amgen announced that new data from the Repatha (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain, Aug. 26-30, 2017. New data includes additional efficacy and safety analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound imaging trial (GLAGOV).
“Data from the Repatha clinical trial program continue to reinforce the value of this innovative medicine for patients at risk of a heart attack or stroke,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “We look forward to sharing the breadth of data demonstrating Repatha’s ability to lower LDL cholesterol and reduce cardiovascular events, including the effect of Repatha in patients with a history of stroke.”
Data from the Repatha cardiovascular outcomes trial assessing the effect of Repatha on cardiovascular outcomes in patients with a history of stroke will be presented in a late-breaking science session (Clinical Trial Update 2) along with a new analysis from the GLAGOV trial. A second analysis of the Repatha cardiovascular outcomes trial, assessing the efficacy and safety of achieving very low low-density lipoprotein cholesterol (LDL-C) levels with Repatha, will be presented in the late-breaking Clinical Trial Update 1 session.
Amgen-sponsored abstracts at ESC Congress 2017 include:
Repatha
Clinical
Late-Breaking Science Sessions
- Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Trial Update 1, Monday, Aug. 28, 2:30 – 2:45 p.m. CEST - Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights on the GLAGOV Trial
Clinical Trial Update 2, Tuesday, Aug. 29, 4:45 – 5 p.m. CEST - Further Cardiovascular OUtcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (Focus on Cerebrovascular Disease)
Clinical Trial Update 2, Tuesday, Aug. 29, 5 – 5:15 p.m. CEST
Poster Sessions
- Efficacy and Safety of Evolocumab Compared With Continued Lipoprotein Apheresis: Results of a Randomised, Controlled, Open-Label Study
Late-Breaking Science Posters, Sunday, Aug. 27, 8:30 a.m. – 6 p.m. CEST
Moderated Session, 3:35 – 4:25 p.m. CEST - Evolocumab Treatment in Paediatric Patients With Homozygous Familial Hypercholesterolaemia: the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)
Rapid Fire Session, Lipid Lowering Therapy in Primary Cardiovascular Prevention, Monday, Aug. 28, 12:12 – 12:21 p.m. CEST - Evolocumab Lowers Plasma Lp(a) Concentration by Two Kinetic Modes of Action: From the FLOREY Study
Lipid Metabolism, Monday, Aug. 28, 8:30 a.m. – 12:30 p.m. CEST
Moderated Session: 10:05 – 10:55 a.m. CEST - Is Lipoprotein(a) Metabolism Linked to the Transport and Catabolic Rates of Apolipoprotein B-100 Containing Lipoproteins?
Lipid Metabolism, Monday, Aug. 28, 8:30 a.m. – 12:30 p.m. CEST
Moderated Session: 10:05 – 10:55 a.m. CEST
Observational Research
- Changes in Lipid-lowering Therapy Prescription Patterns Following a Second Cardiovascular Disease Event
Lipid-lowering Therapy: Old Faces and New Issues, Saturday, Aug. 26, 11 a.m. – 4 p.m. CEST
Moderated Session, 12:35 – 1:25 p.m. CEST - Evaluation of Statin Users, People With Hypercholesterolemia, and Cardiovascular Disease Patients in the Japan Medical Data Center Claims Database
Poster Session 1: Treatment of Dyslipidaemia, Saturday, Aug. 26, 11 a.m. – 4 p.m. CEST - Statin Use Among HIV-Infected Adults by Cardiovascular Disease Risk Status
Lipid-lowering Therapy: Old Faces and New Issues, Saturday, Aug. 26, 11 a.m. – 4 p.m. CEST
Moderated Session, 12:35 – 1:25 p.m. CEST - Adherence to Intensive Medical Management in the Year Following Hospitalization for Myocardial Infarction
Poster Session 5: Prevention – Epidemiology, Monday, Aug. 28, 2 – 6 p.m. CEST - Characterizing Familial Hypercholesterolemia in an Electronic Health Record (EHR) Database
Poster Session 6: Lipids, Obesity and Metabolic Syndrome, Tuesday, Aug. 29, 8:30 a.m. – 12:30 p.m. CEST
Health Economics
- Lack of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Attainment Among High-Risk Patients Using Highor Moderate Intensity Statin Therapy in Germany
Best Posters 3: Best Posters in New Targets in Cardiovascular Drug Assessment, Sunday, Aug. 27, 2 – 6 p.m. CEST
Discussant Review, 3:35 – 4:25 p.m. CEST
Corlanor® (ivabradine)
Observational Research
- Increased Heart Rate is Independently Associated With Worse Survival in Pediatric Patients with Dilated Cardiomyopathy: a Multicenter Study From the Pediatric Cardiomyopathy Registry
Contemporary Management of Risk Factors in Congenital Heart Disease, Sunday, Aug. 27, 8:57 – 9:06 a.m. CEST
Filed Under: Drug Discovery
